| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/18/1999 | WO1999007711A1 3-substituted 3,4,5,7-tetrahydro-pyrrolo3',4':4,5 thieno2,3-dpyrimidine derivatives, their preparation and use as 5ht antagonists |
| 02/18/1999 | WO1999007710A1 Macrolides with antitumor activity |
| 02/18/1999 | WO1999007709A1 Methods of preparing and purifying 9-nitro-20-camptothecin |
| 02/18/1999 | WO1999007708A1 1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives as ampa/kainate receptor inhibitors |
| 02/18/1999 | WO1999007707A1 8-SUBSTITUTED-9H-1,3-DIOXOLO/4,5-h//2,3/BENZODIAZEPINE DERIVATIVES, AS AMPA/KAINATE RECEPTOR INHIBITORS |
| 02/18/1999 | WO1999007705A1 Purine inhibitor of protein kinases, g proteins and polymerases |
| 02/18/1999 | WO1999007703A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 02/18/1999 | WO1999007700A1 Bicyclic compounds as ligands for 5-ht1 receptors |
| 02/18/1999 | WO1999007699A1 Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting immuno-deficiency |
| 02/18/1999 | WO1999007696A1 Quinolizine carboxylic acid derivatives |
| 02/18/1999 | WO1999007695A2 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST |
| 02/18/1999 | WO1999007694A1 Compounds and uses thereof |
| 02/18/1999 | WO1999007693A1 Benzothiophenes |
| 02/18/1999 | WO1999007692A2 New epothilone derivatives, method for producing same and their pharmaceutical use |
| 02/18/1999 | WO1999007681A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 02/18/1999 | WO1999007679A1 Peptidyl compounds having mmp and tnf inhibitory activity |
| 02/18/1999 | WO1999007678A1 Indole derivatives as mcp-1 receptor antagonists |
| 02/18/1999 | WO1999007677A1 2-acylaminopropanamines as tachykinin receptor antagonists |
| 02/18/1999 | WO1999007675A1 Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| 02/18/1999 | WO1999007672A1 Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
| 02/18/1999 | WO1999007670A1 Anthranilic acid analogs |
| 02/18/1999 | WO1999007669A1 Anthranilic acid analogs |
| 02/18/1999 | WO1999007668A1 Non-steroidal ligands for the estrogen receptor |
| 02/18/1999 | WO1999007667A1 Novel ethylamine derivatives |
| 02/18/1999 | WO1999007666A1 Amine derivatives and process for producing the same |
| 02/18/1999 | WO1999007419A1 Dialysis solutions containing water soluble vitamins and nutrients |
| 02/18/1999 | WO1999007418A2 Sterile bioerodible implant device with improved biocompatability and method |
| 02/18/1999 | WO1999007417A1 Hemostatic tissue sealants |
| 02/18/1999 | WO1999007412A1 Remedies for diseases associated with bone resorption |
| 02/18/1999 | WO1999007411A1 Remedies for complications of diabetes |
| 02/18/1999 | WO1999007409A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 02/18/1999 | WO1999007405A1 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6 |
| 02/18/1999 | WO1999007400A1 Dietary supplements containing natural ingredients |
| 02/18/1999 | WO1999007399A1 Pharmaceutical composition containing a mixed extract of phellodendron amurense ruprecht cortex and patrinia scabiosaefolia fisch. for treatment of hepatitis c |
| 02/18/1999 | WO1999007392A1 Isoflavone-containing compositions |
| 02/18/1999 | WO1999007388A1 Method for promoting weight and fat loss with a composition comprising hydroxycitrate, carnitine and a pyruvate promotor |
| 02/18/1999 | WO1999007387A1 Chromium/biotin treatment of type ii diabetes |
| 02/18/1999 | WO1999007386A1 Composition and method of treating cancer with tannic acid and tannin complexes |
| 02/18/1999 | WO1999007383A1 Composition and method for regulating cell proliferation and cell death |
| 02/18/1999 | WO1999007382A1 Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases |
| 02/18/1999 | WO1999007381A1 Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors |
| 02/18/1999 | WO1999007379A1 5,6-HETEROARYL-DIPYRIDO[2,3-b:3',2'-f]AZEPINES AND THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION |
| 02/18/1999 | WO1999007378A1 Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| 02/18/1999 | WO1999007377A1 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity |
| 02/18/1999 | WO1999007376A1 Use of nk-1 receptor antagonists for treating mania |
| 02/18/1999 | WO1999007375A1 Use of nk-1 receptor antagonists for treating aggressive behaviour disorders |
| 02/18/1999 | WO1999007374A1 Use of nk-1 receptor antagonists for treating aggressive behaviour |
| 02/18/1999 | WO1999007373A1 Use of nk-1 receptor antagonists for treating mania |
| 02/18/1999 | WO1999007371A1 Treatment of prostate cancer |
| 02/18/1999 | WO1999007370A1 Oral solid pharmaceutical compositions containing nicorandil for a modulated release and the process for their preparation |
| 02/18/1999 | WO1999007369A1 Compounds and pharmaceutical compositions thereof for eliciting analgesic effects |
| 02/18/1999 | WO1999007368A1 Antimutagenic agents |
| 02/18/1999 | WO1999007365A1 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation |
| 02/18/1999 | WO1999007364A1 Immunosuppression by photochemotherapy |
| 02/18/1999 | WO1999007363A1 Use of the compound 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamido acetate for the production of an anti-inflammatory drug with prevention of gastric hypersecretion and renal impairment |
| 02/18/1999 | WO1999007362A1 A PROCESS FOR STABIlIZING LEVOGYRE ASCORBIC ACID (LAA) AND STABLE LAA COMPOSITIONS |
| 02/18/1999 | WO1999007361A1 Methods for controlling gram negative bacteria in mammals |
| 02/18/1999 | WO1999007360A1 Compounds and uses thereof |
| 02/18/1999 | WO1999007359A1 Use of cholinesterase inhibitors for treating attention deficit disorders |
| 02/18/1999 | WO1999007358A1 Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2 |
| 02/18/1999 | WO1999007356A1 Nicotine antagonists for neuropsychiatric disorders |
| 02/18/1999 | WO1999007355A1 Idebenone-containing preparation for percutaneous administration |
| 02/18/1999 | WO1999007354A2 Compositions, apparatus and methods for facilitating surgical procedures |
| 02/18/1999 | WO1999007352A2 Method for promoting expression of ldl receptor gene |
| 02/18/1999 | WO1999007351A2 Indole derivatives and their use as mcp-1 antagonists |
| 02/18/1999 | WO1999007350A2 Chemo-protection |
| 02/18/1999 | WO1999007342A1 Prolonged release active agent dosage form adapted for gastric retention |
| 02/18/1999 | WO1999007341A1 Compositions for nasal administration |
| 02/18/1999 | WO1999007340A1 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
| 02/18/1999 | WO1999007339A1 Compositions for visually improving skin |
| 02/18/1999 | WO1999007337A1 Use of a 2-amino-alkane polyol as agent for treating skin ageing signs |
| 02/18/1999 | WO1999007224A1 Compositions and methods for treating diabetes |
| 02/18/1999 | WO1998051279A3 Method of making microencapsulated dna for vaccination and gene therapy |
| 02/18/1999 | WO1998049290A3 Syndecan interacting proteins and the use thereof |
| 02/18/1999 | WO1998040055A3 Anti-epileptogenic agents |
| 02/18/1999 | WO1998033491A3 Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase |
| 02/18/1999 | WO1998029108A3 Compositions and methods for restoring a normal pattern of imprinting to cells |
| 02/18/1999 | WO1998027972A3 Anti-amyloidogenic agents |
| 02/18/1999 | WO1998014593A3 Human telomerase catalytic subunit |
| 02/18/1999 | DE19746654A1 Use of 4,4-di:aryl-butadiene derivatives as photostable UV filter compounds |
| 02/18/1999 | DE19736265A1 Medicament containing salicyl alcohol and maleic or fumaric acid |
| 02/18/1999 | DE19735410A1 New stable fumarate salt of pyrimidinol derivative dopamine D3 receptor ligand, having improved solubility and suitable for oral administration |
| 02/18/1999 | DE19733651A1 Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole Aqueous aerosol formulations containing biologically active molecules Marko and method for generating appropriate aerosols |
| 02/18/1999 | CA2340629A1 Method for promoting weight and fat loss with a composition comprising hydroxycitrate, carnitine and a pyruvate promotor |
| 02/18/1999 | CA2300391A1 3-substituted 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5]thieno[2,3-d]pyrimidine derivatives |
| 02/18/1999 | CA2300373A1 Immunomodulator exhibiting antimicrobial and antimycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as pulmonary chronic and non-specific conditions, sexually transmitted diseases and the resulting immuno-deficiency |
| 02/18/1999 | CA2300302A1 8-substituted-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives, as ampa/kainate receptor inhibitors |
| 02/18/1999 | CA2300273A1 Amine derivatives and method for producing the same |
| 02/18/1999 | CA2300142A1 1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives as ampa/kainate receptor inhibitors |
| 02/18/1999 | CA2299630A1 Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 02/18/1999 | CA2299608A1 New epothilone derivatives, method for producing same and their pharmaceutical use |
| 02/18/1999 | CA2299554A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 02/18/1999 | CA2299346A1 Dialysis solutions containing water soluble vitamins and nutrients |
| 02/18/1999 | CA2299336A1 Hemostatic tissue sealants |
| 02/18/1999 | CA2299322A1 Composition and method of treating cancer with tannic acid and tannin complexes |
| 02/18/1999 | CA2299309A1 Benzothiophenes |
| 02/18/1999 | CA2299298A1 Compositions for nasal administration |
| 02/18/1999 | CA2299286A1 Bicyclic compounds as ligands for 5-ht1 receptors |
| 02/18/1999 | CA2299270A1 Use of a retinoid type compound to modulate in vivo the decoupling activity of the protein ucp2 |
| 02/18/1999 | CA2299269A1 Macrolides with antitumor activity |